QDOSE to be part of commercial partnership with Telix

We are proud to announce that the dosimetry software QDOSE® designed by us and our development partner Quantinm AB will now become part of a commercial partnership with Telix. Telix intends to integrate the platform into its therapeutic radiopharmaceutical programmes...

Visiting SNMMI 2024 in Toronto

Summer 2024 is coming up and as every year we are returning to the SNMMI 2024 in Toronto, Canada on June 8-11. Our two General Managers, Dr. Andreas Kluge and Andreas Fintelmann, and the CEO of ABX-CRO INC, Moritz Kallerhoff, will be there again accompanied by our...

Visiting Chile for TWC 2024

This year we will start our conference activities in Santiago, Chile for the 7th Theranostics World Congress. From March 22 to 24 you can find us at booth #A06 and talk with Dr. Andreas Kluge and Andreas Fintelmann, our General Managers, about how ABX-CRO can help you...

Phase 2 study for improvement of prostate cancer diagnosis

Prostate cancer awareness month may already be over, but men’s health remains an important topic. We are therefore most pleased to announce that ABX-CRO was chosen to collaborate with Curasight in a phase 2 study to improve the diagnosis of prostate cancer. The...

TRP EU in December 2023

We are happy to announce that our last conference this year will be the Targeted Radiopharmaceuticals Summit Europe. Come and find us in Berlin from 5 to 7 December. Join us for our talks: “Using multiple legislations to optimise clinical trial conduct (EU & USA)”...
Untitled Document